You are here

Brazil suspends trials of China's Sinovac Covid-19 vaccine due to 'adverse effect'

nz_sinovac_101120.jpg
Brazil's health regulator said on Monday it had suspended clinical trials for China's Sinovac coronavirus vaccine, due to a "severe adverse effect" that took place on Oct 29 but did not immediately provide further details.

[SAO PAULO] Brazil's health regulator said on Monday it had suspended clinical trials for China's Sinovac coronavirus vaccine, due to a "severe adverse effect" that took place on Oct 29 but did not immediately provide further details.

Sao Paulo's medical research institute Butantan, which is conducting the Sinovac trials in Brazil, said it "was surprised" by the decision.

The head of Butantan, Dimas Covas, speaking to local broadcaster TV Cultura, said the decision was related to a "death" but said he found the regulator announcement strange "because it's a death unrelated to the vaccine." "As there are more than 10,000 volunteers at this moment, deaths can occur... It's a death that has no relation with the vaccine and as such it is not the moment to interrupt the trials," Mr Covas said.

The health regulator, Anvisa, did not specify whether the incident took place in Brazil - where trials are being conducted - or in another country. It also did not say why news of the October event was being communicated only now.

Sinovac did not immediately respond to requests for comment.

Your feedback is important to us

Tell us what you think. Email us at btuserfeedback@sph.com.sg

No other country conducting trials of Sinovac's experimental vaccine has announced a suspension. Late-stage trials are also being conducted in Indonesia and Turkey.

Sinovac's vaccine is among the three experimental Covid-19 vaccines that China has been using to inoculate hundreds of thousands of people under an emergency use programme, and a Chinese health official said on Oct 20 that serious side effects have not been observed in clinical trials.

REUTERS

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes